Management of high-risk lesions is known to be variable, in part due to gaps in evidence. However, newer understanding of the natural history of these lesions has led to evolving approaches and inspired a national multidisciplinary effort to achieve consensus in approach. This webinar will introduce the new joint SBI and ASBrS Benign Breast Disease consensus pathways, highlight important radiologic and pathologic features of high-risk lesions, and discuss essential short-term and long-term management considerations after a high-risk lesion diagnosis. This webinar includes Q&A from the live audience.
CME Information
CME Released: 06/18/2025 CME Expires: 06/17/2028
Satisfactory Completion: Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Joint Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Society of Breast Imaging. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Amedco Joint Accreditation Provider Number: 4008163
ACCME Credit Designation Statement, Physicians: Amedco LLC designates this material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest: The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved. (C7 SCS 6.1-6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
| Name | Commercial Interest: Relationship |
|---|---|
| Samantha Heller, MD, FSBI | N/A |
| Dana Ataya, MD | N/A |
| Nuria Gramkee | N/A |
| Ryan Dixon | N/A |
Acknowledgement of Financial Commercial Support: No financial commercial support was received for this educational activity.
Acknowledgement of In-Kind Commercial Support: No in-kind commercial support was received for this educational activity.
- Understand high risk lesions, including histopathology, imaging, and expected upgrade rates and review why there has been variability in management.
- Introduce the ASBrS-SBI Benign Breast Disease High Risk Lesion project.
- Review ASBrS-SBI recommendations for high risk lesions.
